RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Panacos was engaged in the discovery, development and commercialization of small molecule drugs to treat or prevent serious infectious disease. Its lead antiviral product was PA-457, which at the time was the first in a new class of drugs to treat HIV infection. Pappas Ventures teamed up with Ampersand Ventures to take Panacos public via a reverse merger with V.I. Technologies in 2005.
The rights to Panacos’s HIV program were acquired by Myriad Pharmaceuticals in 2009.
Panacos Pharmaceuticals
Watertown, MA
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.